Vertex Pharmaceuticals PT Raised to $85.00 (VRTX)
Stock analysts at Goldman Sachs Group Inc. lifted their target price on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $79.00 to $85.00 in a report issued on Wednesday, Analyst Ratings.Net reports. Goldman Sachs Group Inc.’s price objective indicates a potential upside of 10.23% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research note to investors on Wednesday, August 21st. They set an “outperform” rating and a $105.00 price target on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $80.00 to $88.00 in a research note to investors on Tuesday, July 30th. They now have a “market perform” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) to $84.00 in a research note to investors on Tuesday, July 30th.
One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $89.84.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 1.18% on Wednesday, hitting $77.11. 1,684,624 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 52-week low of $38.44 and a 52-week high of $89.96. The stock’s 50-day moving average is $78.04 and its 200-day moving average is $73.28. The company’s market cap is $17.952 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Monday, July 29th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.18) by $0.08. The company had revenue of $310.80 million for the quarter, compared to the consensus estimate of $308.02 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was down 25.7% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.43 EPS for the current fiscal year.
In other Vertex Pharmaceuticals news, EVP Peter Mueller unloaded 7,500 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $77.22, for a total value of $579,150.00. Following the completion of the sale, the executive vice president now directly owns 144,400 shares of the company’s stock. The sale was disclosed in a filing with the SEC, which is available at this link.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.